The Lungitude Foundation aims to improve survival rates and outcomes for lung transplant recipients & their carers.
Promoting and facilitating donations, fundraising programs and contributions from the general public, philanthropic organisations and the corporate sector.
Promoting and fostering co-operation and mutually beneficial activity and support among other organisations undertaking activities related to our purpose.
Promoting and fostering advocacy and community awareness programs relating to lung and other organ transplantations related to our purpose.
Facilitating world-class medical and health research projects.
Promoting and supporting improvements in medical procedures, treatments and strategies.
Enriching the quality of lives while maximising choices and opportunities.
To facilitate, undertake and publish medical and health research for lung transplantation, and where appropriate other human organ transplants, to address the clinical syndrome of Chronic Lung Allograft Dysfunction (CLAD) and associated diseases and medical conditions including, but not limited to, Bronchiolitis Obliterans Syndrome (BOS), Restrictive Allograft Syndrome (RAS), Cytomegalovirus (CMV) disease, fungal diseases and associated complications; together with promoting and supporting improvements in medical procedures, treatments and strategies for patients pre, during and post-transplantation; and
To maximise the range of choices and opportunities to enrich the quality of their lives of people who need or receive a lung transplant, and/or other organ transplants, and their carers with the aim of reducing patient morbidity and mortality.
The Lungitude Foundation is inspired by The Margaret Pratt Heart Lung Transplant Research Foundation, a registered Australian charity that was established in 1999 by co-founders Margaret and Tony Pratt. Their vision was to encourage, develop and maintain Australia’s world class expertise in the field of organ transplantation by supporting research that addresses the problems faced by children and adults after lung transplantation.
Margaret was diagnosed in 1993 with primary pulmonary hypertension, a rare condition affecting the blood vessels of the lungs, and was the first person in Australia to undergo 3 double lung transplants. Sadly Margaret lost her battle with chronic lung rejection and passed away on 13th September 2009. Margaret was an inspiration to those who had the privilege of knowing her and working with her.
The Margaret Pratt Foundation raised around $1.4 million for The Alfred Lung Transplant Research Team and lay the cornerstone of the vital life-saving work that continues today. An achievement accomplished by a team of dedicated and passionate volunteers who donated their time and skills over a period of 16 years.
The Lungitude Foundation will build on Margaret’s legacy as we further expand and facilitate world-class lung transplant research and services we can all be proud of.